Literature DB >> 760750

The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise.

P J Lijnen, A K Amery, R H Fagard, T M Reybrouck, E J Moerman, A F De Schaepdryver.   

Abstract

1 beta-adrenoceptor blockade with metoprolol provoked, both at rest and during exercise, a decrease of 'active' renin and angiotensin II together with an increase of 'inactive' renin and unchanged 'total' renin. The significant exercise-provoked increases in angiotensin II, plasma renin activity and 'active', 'inactive' and 'total' renin when on placebo, were reduced by metoprolol. 2 No significant change in serum sodium and potassium and in plasma aldosterone was found during beta-adrenoceptor blockade at rest. During exercise plasma aldosterone dropped significantly without any change in serum sodium or potassium. 3 Plasma noradrenaline increased significantly at rest on metoprolol. The increase in plasma noradrenaline and adrenaline during exercise was similar on placebo and on metoprolol.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760750      PMCID: PMC1429426          DOI: 10.1111/j.1365-2125.1979.tb00918.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  INDOCYANINE GREEN CLEARANCE AND ESTIMATED HEPATIC BLOOD FLOW DURING MILD TO MAXIMAL EXERCISE IN UPRIGHT MAN.

Authors:  L B ROWELL; J R BLACKMON; R A BRUCE
Journal:  J Clin Invest       Date:  1964-08       Impact factor: 14.808

2.  Effect of exercise and of prolonged oral administration of propranolol on haemodynamic variables, plasma renin concentration, plasma aldosterone and c-AMP.

Authors:  J Bonelli; W Waldhäusl; D Magometschnigg; J Schwarzmeier; A Korn; G Hitzenberger
Journal:  Eur J Clin Invest       Date:  1977-10       Impact factor: 4.686

3.  [Treatment of essential hypertension with propranolol (author's transl)].

Authors:  F Klumpp; B Braun; D Klaus; R Lemke; J Zehner
Journal:  Dtsch Med Wochenschr       Date:  1976-10-08       Impact factor: 0.628

4.  Atenolol and plasma renin concentration in hypertensive patients.

Authors:  A Amery; P Lijnen; R Fagard; T Reybrouck
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

5.  Direct radioimmunoassay of plasma aldosterone in normal subjects.

Authors:  P Lijnen; A Amery; R Fagard; P Corvol
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

6.  Direct radioimmunoassay of plasma angiotensin II [proceedings].

Authors:  P J Lijnen; A K Amery; R H Fagard
Journal:  Arch Int Physiol Biochim       Date:  1977-12

7.  Relative significance of plasma renin activity and concentration in physiologic and pathophysiologic conditions.

Authors:  P J Lijnen; A K Amery; R H Fagard; T M Reybrouck
Journal:  Angiology       Date:  1978-05       Impact factor: 3.619

8.  Plasma prorenin: cryoactivation and relationship to renin substrate in normal subjects.

Authors:  J E Sealey; C Moon; J H Laragh; M Alderman
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

9.  Inactive renin in human plasma.

Authors:  F H Derkx; J M von Gool; G J Wenting; R P Verhoeven; A J Man in 't Veld; M A Schalekamp
Journal:  Lancet       Date:  1976-09-04       Impact factor: 79.321

10.  Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure.

Authors:  S A Atlas; J E Sealey; J H Laragh; C Moon
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

View more
  14 in total

1.  Effects of mental and physical stress on plasma catecholamine levels before and after beta-adrenoceptor blocker treatment.

Authors:  E Paran; L Neumann; N Cristal
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  Effect of acute administration of propranolol and atenolol on baroreflex function in normal man.

Authors:  A H Deering; D W Harron; J G Riddell; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Exercise haemodynamics and maximal exercise capacity during beta-adrenoceptor blockade in normotensive and hypertensive subjects.

Authors:  M A van Baak; F M Koene; F T Verstappen
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

5.  Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system.

Authors:  S M Freudenthaler; T Schenck; I Lucht; C H Gleiter
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

6.  Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

Authors:  D P Nicholls; J McNeill; P C O'Connor; D W Harron; W J Leahey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

7.  Responses of catecholamines and blood pressure to beta-blockade in diuretic-treated patients with essential hypertension.

Authors:  A Meier; P Weidmann; W H Ziegler
Journal:  Klin Wochenschr       Date:  1982-01-04

8.  Plasma catecholamines, plasma renin activity and haemodynamics during sodium nitroprusside-induced hypotension and additional beta-blockage with bunitrolol.

Authors:  B Stanek; M Zimpfer; S Fitzal; G Raberger
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Unchanged peripheral sympathetic activity following withdrawal of chronic metoprolol treatment. A study of noradrenaline concentrations and kinetics in plasma.

Authors:  G Olsson; M Daleskog; P Hjemdahl; N Rehnqvist
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

10.  Effects of beta 1-adrenoceptor agonism on plasma renin activity in normal men.

Authors:  J Staessen; A Cattaert; A De Schaepdryver; R Fagard; P Lijnen; E Moerman; A Amery
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.